BLTI Related Analyst Ratings
-
Needham & Company Maintains a 'Buy' on Biolase Technology (BLTI); Poised for Better 2012 After HSIC Entanglement Done
-
Needham & Company Maintains a 'Buy' on Biolase Technology (BLTI); Q4 Shortfall, But Outlook Strong
-
Rodman & Renshaw Starts Biolase Technology (BLTI) at Market Outperform
-
Needham & Company Reiterates a 'Buy' on Biolase Technology (BLTI); Great Qtr of Domestic Sales Signals Continued Turnaround
-
Needham & Company Maintains a 'Buy' on Biolase Technology (BLTI); The Turnaround Continues; Raising Estimates & Price Target
-
Needham & Company Maintains a 'Buy' on Biolase Technology (BLTI); Updating Estimates for 3Q10 Actual Results and Other Recent Developments
-
FTN Midwest Upgrades Biolase Technology (BLTI) to Buy
-
Needham Lowers Price Target On Biolase Technology (BLTI) To $7
-
Sidoti & Co Initiates Coverage on Biolase Technnology (BLTI) with a Buy
-
Lazard downgrades BLTI to Hold
Back to BLTI Stock Lookup
